Literature DB >> 16773389

Effect of prior pneumococcal vaccination on clinical outcome of hospitalized adults with community-acquired pneumococcal pneumonia.

A Mykietiuk1, J Carratalà, A Domínguez, A Manzur, N Fernández-Sabé, J Dorca, F Tubau, F Manresa, F Gudiol.   

Abstract

The aim of this study was to evaluate the effect of prior pneumococcal vaccination on the clinical outcome of 554 consecutive hospitalized adults with community-acquired pneumococcal pneumonia from 1995 to 2004, 61 of whom had been vaccinated in the 5 years before admission. Outcome variables that were compared in vaccinated and unvaccinated adults included the occurrence of bacteremia, the time to resolution of pneumonia symptoms, the length of hospital stay, and mortality. Prior pneumococcal vaccination was associated with a lower risk of bacteremia (odds ratio 0.46, 95% CI 0.22-0.98). Compared with unvaccinated patients, vaccine recipients had better clinical outcomes, which included a faster resolution of pneumonia symptoms. The median length of hospital stay was shorter in vaccinated patients (8.0 vs. 9.0 days; p=0.032). Overall case-fatality rates did not differ significantly between groups (1.6% vs. 6.2%; p=0.233). In conclusion, prior pneumococcal vaccination appears to be associated with a lower risk of bacteremia, a faster time to resolution of symptoms, and a shorter hospital stay in adults with pneumococcal pneumonia. The findings presented here provide additional support to the current vaccine recommendations and should encourage healthcare providers to increase pneumococcal vaccine coverage among targeted adult populations.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16773389     DOI: 10.1007/s10096-006-0161-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  20 in total

1.  Early switch and early discharge strategies in patients with community-acquired pneumonia: a meta-analysis.

Authors:  D C Rhew; G S Tu; J Ofman; J M Henning; M S Richards; S R Weingarten
Journal:  Arch Intern Med       Date:  2001-03-12

2.  Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America.

Authors:  J G Bartlett; S F Dowell; L A Mandell; T M File; D M Musher; M J Fine
Journal:  Clin Infect Dis       Date:  2000-09-07       Impact factor: 9.079

3.  Missed opportunities for pneumococcal and influenza vaccination of Medicare pneumonia inpatients--12 western states, 1995.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-10-03       Impact factor: 17.586

4.  Vaccinations in pneumonia (VIP): pneumococcal and influenza vaccination patterns among patients hospitalized for pneumonia.

Authors:  Laura S Greci; David L Katz; James Jekel
Journal:  Prev Med       Date:  2005-04       Impact factor: 4.018

5.  Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Swedish Pneumococcal Vaccination Study Group.

Authors:  A Ortqvist; J Hedlund; L A Burman; E Elbel; M Höfer; M Leinonen; I Lindblad; B Sundelöf; M Kalin
Journal:  Lancet       Date:  1998-02-07       Impact factor: 79.321

6.  Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries.

Authors:  A Ament; R Baltussen; G Duru; C Rigaud-Bully; D de Graeve; A Ortqvist; B Jönsson; J Verhaegen; J Gaillat; P Christie; A S Cifre; D Vivas; C Loiseau; D S Fedson
Journal:  Clin Infect Dis       Date:  2000-09-05       Impact factor: 9.079

7.  Effectiveness of pneumococcal vaccination for elderly people in Catalonia, Spain: a case-control study.

Authors:  Angela Dominguez; Lluis Salleras; David S Fedson; Conchita Izquierdo; Laura Ruiz; Pilar Ciruela; Asuncion Fenoll; Julio Casal
Journal:  Clin Infect Dis       Date:  2005-03-22       Impact factor: 9.079

8.  Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain.

Authors:  Félix Gutiérrez; Mar Masiá; J Carlos Rodríguez; Antonio Ayelo; Bernardo Soldán; Laura Cebrián; Carlos Mirete; Gloria Royo; Alberto M Hidalgo
Journal:  Clin Infect Dis       Date:  2003-01-15       Impact factor: 9.079

9.  Effectiveness of pneumococcal polysaccharide vaccine in older adults.

Authors:  Lisa A Jackson; Kathleen M Neuzil; Onchee Yu; Patti Benson; William E Barlow; Annette L Adams; Christi A Hanson; Lisa D Mahoney; David K Shay; William W Thompson
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

10.  Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.

Authors:  Jane E Sisk; William Whang; Jay C Butler; Vishnu-Priya Sneller; Cynthia G Whitney
Journal:  Ann Intern Med       Date:  2003-06-17       Impact factor: 25.391

View more
  22 in total

1.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

Review 2.  Sepsis: definition, epidemiology, and diagnosis.

Authors:  Andrew Lever; Iain Mackenzie
Journal:  BMJ       Date:  2007-10-27

3.  Pneumococcal and influenza vaccination status of hospitalized adults with community acquired pneumonia and the effects of vaccination on clinical presentation.

Authors:  Ezgi Demirdogen Cetinoglu; Esra Uzaslan; Abdullah Sayıner; Aykut Cilli; Oguz Kılınc; Aysın Sakar Coskun; Armağan Hazar; Nurdan Kokturk; Ayten Filiz; Mehmet Polatli
Journal:  Hum Vaccin Immunother       Date:  2017-07-14       Impact factor: 3.452

4.  Antibody repertoire profiling with mimotope arrays.

Authors:  Shina Pashova; Christoph Schneider; Stephan von Gunten; Anastas Pashov
Journal:  Hum Vaccin Immunother       Date:  2016-12-08       Impact factor: 3.452

5.  Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries.

Authors:  S M A A Evers; A J H A Ament; G L Colombo; H B Konradsen; R R Reinert; D Sauerland; K Wittrup-Jensen; C Loiseau; D S Fedson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-08       Impact factor: 3.267

6.  [Severe pneumococcal infections in the elderly - preventable by vaccination].

Authors:  H Hof; A Fahr; M Holfelder; R Schwarz; K Oberdorfer
Journal:  Z Gerontol Geriatr       Date:  2013-02       Impact factor: 1.281

Review 7.  Preventing pneumococcal disease in the elderly: recent advances in vaccines and implications for clinical practice.

Authors:  Angel Vila-Corcoles; Olga Ochoa-Gondar
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

8.  Predictors of inhospital mortality and re-hospitalization in older adults with community-acquired pneumonia: a prospective cohort study.

Authors:  Binod Neupane; Stephen D Walter; Paul Krueger; Tom Marrie; Mark Loeb
Journal:  BMC Geriatr       Date:  2010-05-11       Impact factor: 3.921

Review 9.  Vaccines for preventing pneumococcal infection in adults.

Authors:  Sarah Moberley; John Holden; David Paul Tatham; Ross M Andrews
Journal:  Cochrane Database Syst Rev       Date:  2013-01-31

Review 10.  The management of community-acquired pneumonia in the elderly.

Authors:  Paola Faverio; Stefano Aliberti; Giuseppe Bellelli; Giulia Suigo; Sara Lonni; Alberto Pesci; Marcos I Restrepo
Journal:  Eur J Intern Med       Date:  2013-12-17       Impact factor: 4.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.